PubMed · NCBI

Поиск статей PubMed

Ключевые слова, автор, журнал, годы — результаты из PubMed, аннотации с переводом на русский, закладки в браузере.

Найдено: 3 214

Страница 261 из 322
  1. mSystems · 2020 · PMID 33051377

    Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV.

    Taylor BC, Weldon KC, Ellis RJ, Franklin D, McDonald D, Humphrey G et al.

    Alterations in the gut microbiome are associated with neurocognition and related disorders, including in the context of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. However, the connection between the gut microbiome and cognitive decline, gauged by increased dependence in instrumental activities of daily living (IADL), remains largely unexplored in the context of these diseases. Here we characterized the gut microbiome using 16S rRNA amplicon sequencing and untargeted metabolomics with liquid chromatography-mass spectrometry from 347 people with HIV, HIV and HCV, or neither, all of whom underwent a comprehensive neuropsychiatric assessment. We observed that IADL-dependent and -independent HIV-monoinfected (HIV-positive [HIV+]/HCV-negative [HCV-]) and coinfected (HIV+/HCV+) individuals have distinct gut microbiomes. Moreover, we found that dependent individuals with HIV or HIV and HCV were enriched in Bacteroides These results may have implications for the characterization of cognitive decline, as well as the development of potential prevention and treatment strategies for individuals infected with HIV and/or HCV. Of particular interest is the possibility that dietary interventions that are known to modify the microbiome could be used to shift the microbiome toward more favorable states for preserving independence.IMPORTANCE The microbes in the gut and the chemicals they produce by metabolism have been linked to brain function. In earlier work, we showed that infection with two viruses, HIV and HCV, changed the gut microbes and metabolism in ways that were associated with a lifetime history of major depressive disorder. Here, we extend this analysis looking at a measurement of independence in daily living. We find that in individuals with HIV, whether or not they also have HCV, those who reported reduced independence were enriched in a genus of bacteria called Bacteroides This result is interesting because Bacteroides is strongly associated with diets low in carbohydrates and high in animal protein, suggesting that diet changes may help preserve independent living in people living long-term with HIV (although clinical intervention trials would be needed in order to confirm this).

    PubMed ↗
  2. Front Microbiol · 2022 · PMID 36458183

    Viral metagenomics combined with metabolomics reveals the role of gut viruses in mouse model of depression.

    Duan J, Wang W, Jiang T, Bai X, Liu C

    Depression is a heterogeneous mental disorder that has been linked to disturbances in the gut microbiome. As an essential part of the gut microbiome, gut virome may play critical roles in disease progression and development. However, the relationship between the effect of gut virome on neurotransmitter metabolism and depression is unknown. We evaluated the alterations of gut virome and neurotransmitters in chronic restraint stress (CRS)-induced mouse model of depression based on viral metagenomics and LC-MS/MS metabolomics analyses. The results reveal that the gut virome profile of CRS group differed significantly from CON group. Microviridae was the most abundant differential viral family in both groups, followed by Podoviridae, while Siphoviridae was only enriched in CRS group of the top 100 differential viruses. The differential viruses that predicted to Enterobacteriaceae phage, Gammaproteobacteria phage and Campylobacteraceae phage were enriched in CRS group. Furthermore, 12 differential neurotransmitters primarily involved in the tryptophan metabolism pathway were altered in depressive-like mice. Besides, tryptamine and 5-methoxytryptamine hydrochloride were strongly associated with differential viruses belonging to Podoviridae and Microviridae. Our findings provide new insight into understanding the potential role of the gut virome and metabolites in depression.

    PubMed ↗
  3. Health Sci Rep · 2026 · PMID 42707775

    Major Depressive Disorder Signatures: A Review of Artificial Intelligence (AI)-Powered Insights Into Gut Dysbiosis.

    Keshvari NZ, Sarkhab SAMN, Shahmoradi T, Pourashory M, Esmaeili A, Saleki K et al.

    BACKGROUND AND AIMS: Major Depressive Disorder (MDD) is a highly common neuropsychiatric disorder globally. A variety of factors contribute to the neuropathology of MDD. Microbiome research in neuropsychiatric disorders such as MDD has recently attracted attention. Indeed, the gut-brain axis could influence the course of MDD through metabolites such as Gamma-Aminobutyric Acid (GABA), Quinolinate, and other factors. Such metabolites may modulate the balance of excitatory and inhibitory signals. Moreover, MDD features abundant hyperinflammatory bacteria, whereas anti-inflammatory butyrate-synthesizing genera are decreased. METHODS: Despite mounting evidence on the implications for the microbiome in MDD, it is unclear whether a bidirectional or causal relationship is in effect. To overcome this challenge, researchers have utilized AI tools to investigate the complex association between the microbiome and MDD. RESULTS: Additionally, there is no solid biomarker recognized for diagnosis and prognosis of MDD, while further application of AI using ML protocols, such as random forest, NNs, SVM, and DL models, could offer a rather solid and reliable comprehension of the complicated nature of microbiome-MDD interplay. CONCLUSIONS: The present article reviews microbiome alterations as well as inflammatory and metabolic pathways in MDD with a focus on AI technology including support vector machines (SVM), random forests (RF), deep neural networks (DNNs), and autoencoders, which are used to identify microbial biomarkers, predict treatment results, and support personalized medicine.

    PubMed ↗
  4. Int J Mol Sci · 2022 · PMID 36555535

    Clinical Evidence on the Potential Beneficial Effects of Probiotics and Prebiotics in Cardiovascular Disease.

    Pavlidou E, Fasoulas A, Mantzorou M, Giaginis C

    The 'gut microbiome'-the hundreds of trillions of bacteria in the human gastrointestinal tract-serves several functions. The gut microbiome includes all the microorganisms, bacteria, viruses, protozoa, and fungi in the gastrointestinal tract and their genetic material. It helps digest indigestible foods and produces nutrients. Through the metabolism of sugars and proteins, it helps the intestinal barrier, the immune system, and metabolism. Some bacteria, such as those in the gut microbiome, cause disease, but others are essential to our health. These "good" microbes protect us from pathogens. Numerous studies have linked an unhealthy gut microbiome to obesity, insulin resistance, depression, and cardiometabolic risk factors. To maximize probiotic benefits in each case, knowledge of probiotic bacterial strains and how to consume them should be increased. This study aims to examine the benefits of probiotic and prebiotic organisms on cardiovascular health, specifically on heart disease, coronary heart disease, stroke, and hypertension. To complete the research, a literature review was conducted by gathering clinical studies and data. The clinical evidence demonstrates the beneficial effect of probiotics and prebiotic microorganisms on the gut microbiome, which has multiple benefits for overall health and especially for cardiovascular diseases.

    PubMed ↗
  5. BMJ Open · 2026 · PMID 42901599

    Protocol for mixed methods study exploring the gut-brain health among South Indian population.

    Katchhi MS, Ming LC, N D, Bhandari BS, Ahmad A, Dhoddametikurke Siddappa U et al.

    INTRODUCTION: Depressive disorders are a major cause of disability worldwide and are frequently accompanied by somatic manifestations, particularly gastrointestinal (GI) symptoms. Emerging evidence implicates the gut–brain axis in the pathophysiology of depression, yet domain-wise characterisation of GI symptoms across stratified depression severity remains underexplored in the Indian context. Variations in diet, microbiota composition and cultural patterns of somatisation further necessitate region-specific evidence. This study aims to perform domain-wise analysis of GI symptoms across varying levels of depression severity among adult psychiatric outpatients. METHODS/DESIGN: This hospital-based mixed-method study will be conducted in the psychiatry outpatient department of a tertiary care centre in South India. Approximately 300 adults (18–60 years) with newly diagnosed depression and Hamilton Depression Rating Scale-17 (HAMD-17) score ≥8 will be recruited. GI symptoms will be assessed using the GI Symptom Rating Scale (GSRS) across five domains: reflux, abdominal pain, indigestion, diarrhoea and constipation. Sociodemographic and clinical variables including body mass index, lifestyle factors, dietary habits and sleep duration will be recorded. Primary analysis will assess the correlation between total GSRS and HAMD-17 scores, while secondary analyses will compare domain-wise GI symptoms across depression severity groups and identify independent predictors using multivariable regression. A qualitative subsample will undergo semi-structured interviews to explore perceived gut–brain interactions. Statistical analysis will be performed using SPSS and R, with p<0.05 considered significant. ETHICS AND DISSEMINATION: This study has been approved by the Institutional Ethics Committee (IEC) of KLE College of Pharmacy, Bengaluru. Study results will be disseminated through national and international meetings and peer-reviewed publications (IEC reference number: KLECOPBLR/2025-26).

    PubMed ↗
  6. Neurobiol Pain · 2021 · PMID 34409198

    Postoperative pain and the gut microbiome.

    Brenner D, Shorten GD, O'Mahony SM

    In excess of 300 million surgical procedures are undertaken worldwide each year. Despite recognition of the prevalence of postoperative pain, and improvements in pain management techniques, poorly controlled postoperative pain remains a major unresolved challenge globally. An estimated 71% and 51% of patients experience moderate to severe pain after surgery in in-patient and outpatient settings, respectively. Inadequately controlled pain after surgery is associated with significant perioperative morbidity including myocardial infarction and pulmonary complications. As many as 20-56% of patients develop chronic pain after commonly performed procedures such as hernia repair, hysterectomy, and thoracotomy. Traditional analgesics and interventions are often ineffective or partially effective in the treatment of postoperative pain, resulting in a chronic pain condition with related socio-economic impacts and reduced quality of life for the patient. Such chronic pain which occurs after surgery is referred to as Persistent Post-Surgical Pain (PPSP). The complex ecosystem that is the gastrointestinal microbiota (including bacteria, fungi, viruses, phage) plays essential roles in the maintenance of the healthy state of the host. A disruption to the balance of this microbiome has been implicated not only in gastrointestinal disease but also neurological disorders including chronic pain. The influence of the gut microbiome is well documented in the context of visceral pain from the gastrointestinal tract while a greater understanding is emerging of the impact on inflammatory pain and neuropathic pain (both of which can occur during the perioperative period). The gut microbiome is an essential source for driving immune maturation and maintaining appropriate immune response. Given that inflammatory processes have been implicated in postoperative pain, aberrant microbiome profiles may play a role in the development of this type of pain. Furthermore, the microorganisms in our gut produce metabolites, neurotransmitters, and neuromodulators which interact with their receptors to regulate peripheral and central sensitisation associated with chronic pain. Microbiota-derived mediators can also regulate neuroinflammation, which is associated with activation of microglia as well as infiltration by immune cells, known to modulate the development and maintenance of central sensitisation. Moreover, risk factors for developing postoperative pain include anxiety, depression, and increased stress response. These central nervous system-related disorders have been associated with an altered gut microbiome and microbiome targeted intervention studies indicate improvements. Females are more likely to suffer from postoperative pain. As gonadal hormones are associated with a differential microbiome and pre-clinical studies show that male microbiome confers protection from inflammatory pain, it is possible that the composition of the microbiome and its by-products contribute to the increased risk for the development of postoperative pain. Very little evidence exists relating the microbiome to somatic pain. Here we discuss the potential role of the gut microbiome in the aetiology and pathophysiology of postoperative pain in the context of other somatic pain syndromes and what is known about microbe-neuron interactions. Investigations are needed to determine the specific role of the gut microbiome in this type of pain which may help inform the development of preventative interventions as well as management strategies to improve patient outcome.

    PubMed ↗
  7. Front Psychiatry · 2022 · PMID 35686183

    Altered Metabolomics in Bipolar Depression With Gastrointestinal Symptoms.

    Guo XJ, Xiong YB, Jia Y, Cui XH, Wu WZ, Tian JS et al.

    OBJECTIVE: Although gastrointestinal (GI) symptoms are very common in patients with bipolar disorder (BD), Few studies have researched the pathomechanism behind these symptoms. In the present study, we aim at elucidate the pathomechanism of GI symptoms in BD through metabolomic analysis. METHOD: BD patients were recruited from Shanxi Bethune Hospital that divided into two groups, each group assessed with the 24-item Hamilton Depression Rating Scale (HAMD-24) according to the presence or absence of GI symptoms. Healthy controls were recruited from the medical examination center of the same hospital. Differential metabolites were identified and further analyzed using Metabo Analyst 3.0 to identify associated metabolic pathways. RESULTS: There were significantly higher HAMD-24 scores in the GI symptoms group than that of non-GI symptoms group (p = 0.007). Based on metabolomic analysis results, we found that the common disturbances metabolic pathway of both two patients groups was ketone body metabolism, and the unique disturbances metabolic pathways of BD with GI symptoms were fatty acid biosynthesis and tyrosine metabolism, and these changes were independent of dietary habits. CONCLUSION: BD patients with GI symptoms exhibited disturbances in fatty acid and tyrosine metabolism, perhaps suggesting that the GI symptoms in BD patients are related to disturbances of the gut microbiome. Both groups of patients jointly exhibit disturbances of ketone body metabolism, which may serve as a biomarker for the pathogenesis of BD patients.

    PubMed ↗
  8. Microorganisms · 2021 · PMID 34946184

    Gut Bacteria and Neuropsychiatric Disorders.

    Dicks LMT, Hurn D, Hermanus D

    Bacteria in the gut microbiome plays an intrinsic part in immune activation, intestinal permeability, enteric reflex, and entero-endocrine signaling. Apart from physiological and structural changes brought about by gut bacteria on entero-epithelial cells and mucus layers, a vast number of signals generated in the gastro-intestinal tract (GIT) reaches the brain via the vagus nerve. Research on the gut-brain axis (GBA) has mostly been devoted to digestive functions and satiety. Less papers have been published on the role gut microbiota play in mood, cognitive behavior and neuropsychiatric disorders such as autism, depression and schizophrenia. Whether we will be able to fully decipher the connection between gut microbiota and mental health is debatable, especially since the gut microbiome is diverse, everchanging and highly responsive to external stimuli. Nevertheless, the more we discover about the gut microbiome and the more we learn about the GBA, the greater the chance of developing novel therapeutics, probiotics and psychobiotics to treat gastro-intestinal disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), but also improve cognitive functions and prevent or treat mental disorders. In this review we focus on the influence gut bacteria and their metabolites have on neuropsychiatric disorders.

    PubMed ↗
  9. bioRxiv · 2024 · PMID 38562901

    Medication Use is Associated with Distinct Microbial Features in Anxiety and Depression.

    Dilmore AH, Kuplicki R, McDonald D, Kumar M, Estaki M, Youngblut N et al.

    This study investigated the relationship between gut microbiota and neuropsychiatric disorders (NPDs), specifically anxiety disorder (ANXD) and/or major depressive disorder (MDD), as defined by DSM-IV or V criteria. The study also examined the influence of medication use, particularly antidepressants and/or anxiolytics, classified through the Anatomical Therapeutic Chemical (ATC) Classification System, on the gut microbiota. Both 16S rRNA gene amplicon sequencing and shallow shotgun sequencing were performed on DNA extracted from 666 fecal samples from the Tulsa-1000 and NeuroMAP CoBRE cohorts. The results highlight the significant influence of medication use; antidepressant use is associated with significant differences in gut microbiota beta diversity and has a larger effect size than NPD diagnosis. Next, specific microbes were associated with ANXD and MDD, highlighting their potential for non-pharmacological intervention. Finally, the study demonstrated the capability of Random Forest classifiers to predict diagnoses of NPD and medication use from microbial profiles, suggesting a promising direction for the use of gut microbiota as biomarkers for NPD. The findings suggest that future research on the gut microbiota's role in NPD and its interactions with pharmacological treatments are needed.

    PubMed ↗
  10. World Psychiatry · 2023 · PMID 37713568

    Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management.

    Berk M, Köhler-Forsberg O, Turner M, Penninx BWJH, Wrobel A, Firth J et al.

    Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug-drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio-environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.

    PubMed ↗